Neste trabalho foram desenvolvidas condições específicas de RP-HPLC para análise de preparações recombinantes e naturais de hLH, de hCG, e de suas subunidades. O hLH e o hCG heterodimérico e suas subunidades e migraram com tempos de retenção (tR) significativamente diferentes, na seguinte ordem de hidrofobicidade crescente: -hCG < -hLH < hCG < hLH < -hCG < -hLH. Nestas condições, onze preparações foram estudadas: o Padrão Internacional recombinante hLH-WHO 96/602, uma preparação comercial recombinante, duas preparações hipofisárias altamente purificadas de hLH, uma preparação recombinante e duas preparações urinárias de hCG e quatro produtos urinários heterogêneos, contendo hLH + hFSH. Todas as preparações de hLH mostraram um tempo de retenção similar para o pico principal (tR = 38,35 ± 0,42 min; DPR = 1,1 %; n = 4 preparações), enquanto o pico principal do hCG migrou cerca de 4% mais rápido, quando comparado a este valor médio. Picos de hLH, hFSH e hCG foram também identificados nas preparações urinárias heterogêneas. O método foi validado para as sete preparações homogêneas, sendo a exatidão, precisão e sensibilidade calculadas com base na curva dose-resposta, altamente linear (r=0,99998; p<0,0001; n=20). A quantificação de diferentes gonadotrofinas nas preparações heterogêneas foi também realizada, embora com claras limitações de exatidão. / Specific RP-HPLC conditions for the analysis of recombinant and native hLH and hCG preparations and of their subunits were set up. Heterodimeric hLH and hCG and their - and - subunits all migrated with significantly different retention times (tR) in the following order of increasing hydrophobicity: -hCG < -hLH < hCG < hLH < -hCG < -hLH. With basis on these conditions, a total of eleven preparations were studied: the International Standard of recombinant hLH-WHO 96/602, a commercial recombinant and two highly purified pituitary hLH, a recombinant and two urinary hCG preparations and four heterogeneous urinary products containing hLH + hFSH. All hLH preparations showed very similar retention times for the main peak (tR = 38.35 ± 0.42 min; RSD = 1.1 %; n = 4 preparations), while the hCG main peak ran about 4 % faster when compared to this average value. Human LH, hFSH and hCG peaks could also be identified in the heterogeneous urinary preparations. Quantitative analysis could be validated for the seven homogeneous preparations and accuracy, precision and sensitivity were calculated on the basis of a highly linear dose-response curve (r=0.99998; p<0.0001; n=20). Quantification of the differents gonadotropins in the heterogeneous urinary preparations was also carried out, though with clear accuracy limitations.

Neste trabalho foram desenvolvidas condições específicas de RP-HPLC para análise de preparações recombinantes e naturais de hLH, de hCG, e de suas subunidades. O hLH e o hCG heterodimérico e suas subunidades e migraram com tempos de retenção (tR) significativamente diferentes, na seguinte ordem de hidrofobicidade crescente: -hCG < -hLH < hCG < hLH < -hCG < -hLH. Nestas condições, onze preparações foram estudadas: o Padrão Internacional recombinante hLH-WHO 96/602, uma preparação comercial recombinante, duas preparações hipofisárias altamente purificadas de hLH, uma preparação recombinante e duas preparações urinárias de hCG e quatro produtos urinários heterogêneos, contendo hLH + hFSH. Todas as preparações de hLH mostraram um tempo de retenção similar para o pico principal (tR = 38,35 ± 0,42 min; DPR = 1,1 %; n = 4 preparações), enquanto o pico principal do hCG migrou cerca de 4% mais rápido, quando comparado a este valor médio. Picos de hLH, hFSH e hCG foram também identificados nas preparações urinárias heterogêneas. O método foi validado para as sete preparações homogêneas, sendo a exatidão, precisão e sensibilidade calculadas com base na curva dose-resposta, altamente linear (r=0,99998; p<0,0001; n=20). A quantificação de diferentes gonadotrofinas nas preparações heterogêneas foi também realizada, embora com claras limitações de exatidão. / Specific RP-HPLC conditions for the analysis of recombinant and native hLH and hCG preparations and of their subunits were set up. Heterodimeric hLH and hCG and their - and - subunits all migrated with significantly different retention times (tR) in the following order of increasing hydrophobicity: -hCG < -hLH < hCG < hLH < -hCG < -hLH. With basis on these conditions, a total of eleven preparations were studied: the International Standard of recombinant hLH-WHO 96/602, a commercial recombinant and two highly purified pituitary hLH, a recombinant and two urinary hCG preparations and four heterogeneous urinary products containing hLH + hFSH. All hLH preparations showed very similar retention times for the main peak (tR = 38.35 ± 0.42 min; RSD = 1.1 %; n = 4 preparations), while the hCG main peak ran about 4 % faster when compared to this average value. Human LH, hFSH and hCG peaks could also be identified in the heterogeneous urinary preparations. Quantitative analysis could be validated for the seven homogeneous preparations and accuracy, precision and sensitivity were calculated on the basis of a highly linear dose-response curve (r=0.99998; p<0.0001; n=20). Quantification of the differents gonadotropins in the heterogeneous urinary preparations was also carried out, though with clear accuracy limitations.

No description available.

c-MYC est un facteur de transcription oncogénique dont l’expression est dérégulée dans 78% des gliomes. On observe d’ailleurs une corrélation positive entre sa surexpression et le grade des gliomes. De plus, cette surexpression serait essentielle à la survie des cellules souches tumorales, cellules qui seraient davantage résistantes à la chimiothérapie et à la radiothérapie en plus d’avoir un caractère plus invasif. Il a aussi été démontré que l’inhibition de c-MYC par ARN interférents peut sensibiliser les cellules cancéreuses à l’apoptose et réduire leur prolifération. Sa surexpression relative dans les glioblastomes (GBM) est signe de la malignité et l’espérance de vie des patients atteints par ces tumeurs est réduite chez les patients plus âgés. c-MYC doit s’hétérodimériser avec MAX, son partenaire obligatoire afin de se lier aux promoteurs de ses gènes cibles contenant des EBox (CANNTG) et ainsi activer leur transcription. Cependant, il a été proposé que MAX pourrait homodimériser et agir comme antagoniste en compétitionnant pour les mêmes sites de reconnaissance que l’hétérodimère c-MYC/MAX sur l’ADN. Notre étude vise donc à évaluer l’effet dose-dépendant d’un traitement exogène de MAX*WT, correspondant à une version tronquée du facteur de transcription MAX, sur différentes lignées cellulaires de GBM. Nous avons d’abord étudié les capacités de la protéine à transloquer dans les cellules par microscopie. Ceci a permis de déterminer que le peptide s’internalise rapidement (15 minutes) pour ensuite s’accumuler au niveau nucléaire (24 h, 48 h). Par la suite, des analyses de FACScan ont démonté qu’un traitement de 72 heures provoque une inhibition de la prolifération cellulaire. À l’aide de chambres de Boyden et d’essais de croissance en sphéroïdes dans une matrice de Matrigel(indice supérieur TM]), nous avons observé une diminution importante du caractère invasif des lignées de gliomes malins suite au traitement avec MAX*WT. Ces résultats démontrent que la protéine MAX*WT semble avoir un effet antinéoplasique sur plusieurs lignées de gliomes malins et que la voie de signalisation de c-MYC pourrait constituer une cible thérapeutique intéressante.

Neste trabalho é descrito um método prático e eficiente para dissociar, em subunidades &alpha; e &beta;, quantidades pequenas (da ordem de microgramas) dos hormônios foliculotrofina (hFSH), luteotrofina (hLH) e tireotrofina (hTSH) humana, nativos e recombinantes. A dissociação destes hormônios foi conseguida incubando-os, durante 16 horas, a 37ºC, com diferentes concentrações de ácido acético: 3M, 5M e 0,4M respectivamente para o hFSH, hLH e hTSH. Nestas condições, uma eficiência de dissociação acima de 98% foi obtida. Esta eficiência foi calculada com base nas determinações de massa dos heterodímeros e das subunidades, realizadas por MALDI-TOF-MS. Uma separação rápida e quantitativa das subunidades, com rendimentos da ordem de 80-90%, foi conseguida por cromatografia líquida de alta eficiência em fase reversa (RP-HPLC) em uma coluna C4. As subunidades foram caracterizadas quanto à pureza, hidrofobicidade, massa molecular e distribuição de carga por HPLC de exclusão molecular e fase reversa, SDS-PAGE e focalização isoelétrica. Quando analisadas quanto à hidrofobicidade, as subunidades mostraram-se aproximadamente iguais, enquanto as subunidades &beta; dos três heterodímeros apresentaram a seguinte escala de hidrofobicidade: &beta;-hFSH < &beta;-hTSH < &beta;-hLH. Com relação à massa molecular relativa (Mr), as subunidades &alpha; e &beta; do hFSH apresentaram as maiores Mr enquanto as subunidades do hLH as menores. A distribuição dos isômeros de carga das subunidades dos três hormônios ocorreu em uma região ácida, para o hFSH, em uma região básica, para o hLH e em uma região intermediária, para o hTSH. As subunidades &alpha; dos três hormônios, quando analisadas via SDS-PAGE, apresentaram praticamente a mesma mobilidade eletroforética, enquanto as subunidades &beta; apresentaram diferentes taxas de migração (mR), sendo mR &beta;-hFSH < mR &beta;-hTSH < mR &beta;-hLH. Diferenças relativas à massa molecular, hidrofobicidade, migração eletroforética e distribuição de carga foram encontradas entre as preparações recombinantes e hipofisárias dos três hormônios. O método descrito é suave, prático e flexível e pode ser adaptado à dissociação de outras glicoproteínas heterodiméricas recombinantes ou nativas. Permite não só estudos e caracterização direta de cada subunidade, como também detectar a presença de subunidades livres em preparações farmacêuticas, que são contaminantes indesejáveis, sendo, portanto, uma ferramenta extremamente útil para o controle de qualidade de produtos farmacêuticos. / In this work a practical and efficient method for the dissociation into &alpha;-and &beta;-subunits of small amounts (microgram range) of pituitaryderived and recombinant human follicle-stimulating hormone (hFSH), human luteotropin (hLH) and human thyrotropin (hTSH) is described. Dissociation was achieved by overnight treatment of the glycoproteins, at 37ºC, with acetic acid in different concentrations: 3M, 5M and 0,4M for hFSH, hLH and hTSH respectively. In these conditions, a dissociation efficiency of > 98% was attained. This efficiency was calculated on the basis of relative mass determinations of the heterodimers and subunits carried out via mass spectrometry (MALDI-TOF-MS). The &alpha;-and &beta;-subunits were rapidly and quantitatively separated by reversed-phase high-performance liquid chromatography (RP-HPLC) on a C4 column with yields of the order of 80-90%. The isolated subunits were characterized concerning their purity, hidrophobicity, molecular mass and charge distribution, via size exclusion and RP-HPLC, SDS-PAGE and isoelectric focusing. When analyzed with relation to the hydrophobicity, the &alpha;-subunits presented approximately the same hydrophobicity, while &beta;-subunits showed the following scale: &beta-hFSH < &beta;-hTSH < &beta;-hLH. Concerning molecular mass, &alpha;- and &beta;-subunits of hFSH were shown to have the highest while hLH subunits the lowest. Charge isomers of the subunits of the three glycohormones were predominantly distributed in an acidic region for hFSH, in a basic region for hLH, and in a wider pH range (acidic and basic) for hTSH. Similar migration rates (mR), analyzed via SDS-PAGE, were observed for the &alpha;-subunits of the three hormones. A greater variation was found for the &beta;-subunits: mR &beta;-hFSH < mR &beta;-hTSH < mR &beta;-hLH. Differences between recombinant and pituitary preparations of three hormones were observed with relation to molecular mass, hydrophobicity, electrophoretic migration and charge distribution. The described method is mild, practical and flexible and can be adapted to dissociate any recombinant or native heterodimeric glycoprotein, allowing studies and direct characterization of each subunit as well as the detection of free subunits that are undesired contaminants in pharmaceutical preparations, being also an extremely useful tool for the quality control of pharmaceutical products.

Neste trabalho é descrito um método prático e eficiente para dissociar, em subunidades &alpha; e &beta;, quantidades pequenas (da ordem de microgramas) dos hormônios foliculotrofina (hFSH), luteotrofina (hLH) e tireotrofina (hTSH) humana, nativos e recombinantes. A dissociação destes hormônios foi conseguida incubando-os, durante 16 horas, a 37ºC, com diferentes concentrações de ácido acético: 3M, 5M e 0,4M respectivamente para o hFSH, hLH e hTSH. Nestas condições, uma eficiência de dissociação acima de 98% foi obtida. Esta eficiência foi calculada com base nas determinações de massa dos heterodímeros e das subunidades, realizadas por MALDI-TOF-MS. Uma separação rápida e quantitativa das subunidades, com rendimentos da ordem de 80-90%, foi conseguida por cromatografia líquida de alta eficiência em fase reversa (RP-HPLC) em uma coluna C4. As subunidades foram caracterizadas quanto à pureza, hidrofobicidade, massa molecular e distribuição de carga por HPLC de exclusão molecular e fase reversa, SDS-PAGE e focalização isoelétrica. Quando analisadas quanto à hidrofobicidade, as subunidades mostraram-se aproximadamente iguais, enquanto as subunidades &beta; dos três heterodímeros apresentaram a seguinte escala de hidrofobicidade: &beta;-hFSH < &beta;-hTSH < &beta;-hLH. Com relação à massa molecular relativa (Mr), as subunidades &alpha; e &beta; do hFSH apresentaram as maiores Mr enquanto as subunidades do hLH as menores. A distribuição dos isômeros de carga das subunidades dos três hormônios ocorreu em uma região ácida, para o hFSH, em uma região básica, para o hLH e em uma região intermediária, para o hTSH. As subunidades &alpha; dos três hormônios, quando analisadas via SDS-PAGE, apresentaram praticamente a mesma mobilidade eletroforética, enquanto as subunidades &beta; apresentaram diferentes taxas de migração (mR), sendo mR &beta;-hFSH < mR &beta;-hTSH < mR &beta;-hLH. Diferenças relativas à massa molecular, hidrofobicidade, migração eletroforética e distribuição de carga foram encontradas entre as preparações recombinantes e hipofisárias dos três hormônios. O método descrito é suave, prático e flexível e pode ser adaptado à dissociação de outras glicoproteínas heterodiméricas recombinantes ou nativas. Permite não só estudos e caracterização direta de cada subunidade, como também detectar a presença de subunidades livres em preparações farmacêuticas, que são contaminantes indesejáveis, sendo, portanto, uma ferramenta extremamente útil para o controle de qualidade de produtos farmacêuticos. / In this work a practical and efficient method for the dissociation into &alpha;-and &beta;-subunits of small amounts (microgram range) of pituitaryderived and recombinant human follicle-stimulating hormone (hFSH), human luteotropin (hLH) and human thyrotropin (hTSH) is described. Dissociation was achieved by overnight treatment of the glycoproteins, at 37ºC, with acetic acid in different concentrations: 3M, 5M and 0,4M for hFSH, hLH and hTSH respectively. In these conditions, a dissociation efficiency of > 98% was attained. This efficiency was calculated on the basis of relative mass determinations of the heterodimers and subunits carried out via mass spectrometry (MALDI-TOF-MS). The &alpha;-and &beta;-subunits were rapidly and quantitatively separated by reversed-phase high-performance liquid chromatography (RP-HPLC) on a C4 column with yields of the order of 80-90%. The isolated subunits were characterized concerning their purity, hidrophobicity, molecular mass and charge distribution, via size exclusion and RP-HPLC, SDS-PAGE and isoelectric focusing. When analyzed with relation to the hydrophobicity, the &alpha;-subunits presented approximately the same hydrophobicity, while &beta;-subunits showed the following scale: &beta-hFSH < &beta;-hTSH < &beta;-hLH. Concerning molecular mass, &alpha;- and &beta;-subunits of hFSH were shown to have the highest while hLH subunits the lowest. Charge isomers of the subunits of the three glycohormones were predominantly distributed in an acidic region for hFSH, in a basic region for hLH, and in a wider pH range (acidic and basic) for hTSH. Similar migration rates (mR), analyzed via SDS-PAGE, were observed for the &alpha;-subunits of the three hormones. A greater variation was found for the &beta;-subunits: mR &beta;-hFSH < mR &beta;-hTSH < mR &beta;-hLH. Differences between recombinant and pituitary preparations of three hormones were observed with relation to molecular mass, hydrophobicity, electrophoretic migration and charge distribution. The described method is mild, practical and flexible and can be adapted to dissociate any recombinant or native heterodimeric glycoprotein, allowing studies and direct characterization of each subunit as well as the detection of free subunits that are undesired contaminants in pharmaceutical preparations, being also an extremely useful tool for the quality control of pharmaceutical products.

Les facteurs de transcription du réseau c-Myc/Max/Mxd assurent le contrôle de la transcription de plus de 1600 gènes. L'hétérodimérisation compétitive entre les membres du réseau et la protéine Max permet des réponses cellulaires opposées. En effet, le complexe c-Myc/Max est associé à l'activation de la transcription de gènes sous l'influence de promoteurs contenant des sites E-Box, pendant que les complexes Mxd/Max permettent l'inhibition de la transcription à ces mêmes promoteurs. Cependant, l'activité oncogénique associée à la surexpression de c-Myc dans plusieurs cancers semble être assurée par l'inhibition de la transcription de gènes cytostatiques causée par l'association de Miz-1 au complexe c-Myc/Max. De manière encourageante, la réintroduction de Mxdl permet de réduire la prolifération et la croissance cellulaire et constitue une avenue thérapeutique intéressante. Cette thèse rapporte l'élucidation de l'identité de résidus spécifiques impliqués dans la reconnaissance moléculaire de Mxdl et de Max et la détermination de la structure hétérodimérique minimale requise afin de permettre une liaison stable à l'ADN. La reconnaissance moléculaire est dictée par des déterminants structuraux spécifiques contenus dans les régions HLH et LZ. L'hétérodimérisation spécifique nécessite 2 étapes essentielles : 1) la déstabilisation des homodimères, assurée par des répulsions électrostatiques à l'interface de dimérisation des 2 domaines, et 2) l'hétérodimérisation avec Max. Dans notre premier article, nous avons confirmé que l'unique résidu acide D112a, situé à l'interface de dimérisation du LZ, prévient la formation des homodimères. Nous avons démontré que le retrait de la charge acide par la mutation D112N ou par l'abaissement du pH permettait d'augmenter de façon équivalente la population homodimérique. De plus, nos résultats démontrent que l'augmentation de l'homodimérisation du LZ et/ou de la région HLH obtenue par la mutation D112N soutient efficacement la liaison à un site E-Box. Le deuxième article a permis l'identification des résidus impliqués dans l'hétérodimérisation spécifique des régions b-HLH-LZ des protéines Mxdl et Max. L'augmentation de l'hydrophobicité de l'interface dimérique de la protéine Max par les mutations N78VH81L (VL) avait ultérieurement permis d'augmenter considérablement l'homodimérisation et de stabiliser la liaison à l'ADN. Dans cette optique prometteuse, nous avons augmenté l'hydrophobicité de l'interface dimérisation du LZ de Mxdl par la mutation D112V. Des essais de digestions enzymatiques et de CD ont confirmés l'augmentation de la stabilité du LZ de Mxdl. Cependant, cette mutation permettant d'accroître le taux d'hélices [alpha] ne permet toutefois pas de stabiliser la liaison à l'ADN. Certaines répulsions électrostatiques, possiblement impliquées dans la déstabilisation des homodimères de Mxdl et obtenues par le rapprochement des régions HLH, ont été hypothétiquement identifiées par modélisation moléculaire. Nous avons ensuite utilisé des essais d'hétérodimérisation limites strictement à certaines régions dimériques pour démontrer que les régions HLH hétérodimérisent de manière favorable indépendamment de la présence de LZ homodimériques. Cependant, la liaison à l'ADN nécessite l'hétérodimérisation des régions LZ même si l'interaction des régions HLH est observée en absence d'ADN. L'hétérodimérisation complète des domaines HLH et LZ, essentielle à la liaison de l'ADN par l'hétérodimère, survient uniquement lorsque l'interaction favorable des régions HLH surpasse la stabilité des LZ homodimériques et soutient indirectement la formation des hétérodimères des régions LZ. Nous avons également fait la démonstration que l'hétérodimérisation précède la liaison à l'ADN tel que proposée par d'autres groupes et ne peut être décrite par le mécanisme d'hétérodimérisation empruntant le «monomer pathway» qui correspondrait à la liaison successive de l'ADN par les monomères de Mxdl et de Max avant l'hétérodimérisation.

The glycoprotein hormone family comprising of Luteinizing Hormone (LH), Chorionic Gonadotropin (hCG), Follicle Stimulating Hormone (FSH) and Thyroid Stimulating Hormone (TSH) plays important role in reproduction and overall physiology of the organism. These hormones are heterodimeric molecules consisting of an identical α subunit non-covalently associated with the hormone-specific β subunit. Both subunits of all these hormones are N-glycosylated. In addition, hCGβ subunit also has four O-linked oligosaccharides located at the C-terminus of the polypeptide(1). The α and β subunits of all these hormones contain five and six disulfide bonds respectively and the crystal structures of hCG and hFSH indicate that both subunits of the hormones belong to the cystine knot family of proteins(2-4). Although the β subunits are hormone specific, there are distinct similarities in these subunits with the 12 cysteines conserved in all these subunits (1). These hormones, because of their unique structural features have proved to be important models for structure–function relationship studies of complex dimeric glycoproteins. Folding of subunits during biosynthesis, role of glycosylation in folding pathways and in vitro and in vivo bioactivity of the hormone, as well as, identification of domains important for subunit association, receptor binding and subsequent signal transduction have been topics of active investigations. The receptors of these hormones belong to the family of G-protein coupled receptors (GPCR) and have unique hormone specific exodomain not present in other members of the GPCR family and characteristic seven transmembrane domains followed by a C terminal domain(5). Primary structure analysis of Glycoprotein hormone receptors family revealed sequence conservation, maximum homology being observed in the transmembrane domain (TMD)(6). Significant homologies could be observed in the hormone specific extracellular domains (ECD) also (7). Despite these homologies, the receptors exhibit exquisite specificity with very low cross reactivity with other members of the hormone family (8). Elucidation of the molecular details of the contacts between the hormone and the receptors has not been achieved so far. Various approaches have been employed to delineate the residues or domains of both hormone and receptors involved in interaction. These include testing of chimeras or mutants of hormones or receptors for changes in activity (9-12), chemical modifications(13) and competition with peptides from either hormones (14) or receptors (15). Polyclonal and monoclonal antibodies against glycoprotein hormones and various fragments of their receptors have been used to determine the role of different domains of both in binding and response (6, 16, 17). However, till date there is no consensus on the specific mechanisms by which the glycoprotein hormone docks onto its receptor. It was proposed that the initial contact between the hormone and the receptor occurs through high affinity binding of the hormone specific β subunit to the Leucine rich regions of the ECD that results in conformational changes in both hormone, as well as, the receptor and brings hormone/ECD complex closer to the TMD of the receptor. The secondary, relatively lower affinity interactions between the hormone and the receptor then take place through common α subunit and exoloops of TMD of the receptor resulting in signal generation (18, 19). Recently a different kind of model has been proposed which suggests that the hormone does not make any direct contacts with the TMD of the receptor. The signal is transduced by the change in contacts between ECD and TMD brought about by hormone’s interaction with ECD(8, 20). The present study was initiated with an overall objective of understanding the molecular details of the hormone receptor interactions of this family, particularly hCG- LH receptor interactions. Two different approaches were employed for this purpose; the first, direct approach being structure elucidation of the members of the glycoprotein hormone family while the second approach uses antibodies against hCG as tools to probe into hormone-receptor interactions. The results obtained using these two approaches have been consolidated in the present thesis and are organized as follows. Chapter 1 is an extensive review of the literature and it builds background for the present work while the exact aim and scope of the present work have been defined in Chapter 2. Chapter 3 describes cloning, expression and purification of recombinant glycoprotein hormones hLH, hCG and single chain derivative of hCG. The Chapter 4 gives details of the molecular aspects of hCG-LH receptor interaction dissected using hCG monoclonal antibodies (MAbs). Chapter 5 discusses implications of the observations made in the present study and states the future directions envisaged. There are a number of endocrinopathies associated with abnormal levels of glycoprotein hormones and treatments of such disorders often demand large quantities of either agonists or antagonists of the hormones. The structure-function relationship studies should help in identifying domains/residues important for subunit interaction, receptor binding, and signal transduction, which would also allow engineering of agonists and antagonists of hormone action. However, structure determination of the glycoprotein hormone family using X-ray crystallography has proved to be a difficult task and it is believed that the heterogeneity in glycosylation is the primary reason for this low success rate in the process of crystallization. The first crystal structure of hCG was that of completely deglycosylated hCG but such a molecule displays antagonistic behavior(2, 3). Use of NMR spectroscopy, the alternate method commonly used for structure determination is often limited by the availability of large quantities of biologically active hormones free of any contaminants. Large quantities of LH, hCG and FSH are also required for treatment of infertile patients suffering from gonadotropin deficiency. The first goal of the present study was thus to produce and purify biologically active recombinant hCG and hLH. Owing to the inherent features of glycoprotein hormones and their potential therapeutic applications, the recombinant expression of these hormones is an important goal from both basic research, as well as, commercial point of view. Considering the above mentioned features it is clear that the expression system used for the hyperexpression of these glycoprotein hormones should also serve as a model system for investigating structure–function relationships and folding of subunits during biosynthesis, in addition to providing sufficient quantities of the hormones for clinical applications. It has been demonstrated that N-linked glycosylation during biosynthesis facilitates protein folding and conformational maturation of glycoprotein hormone subunits into an assembly-competent, biologically active form (21). Therefore, the ideal recombinant expression system should also be able to glycosylate the protein during biosynthesis. The Pichia pastoris yeast expression system was chosen for hyperexpression of glycoprotein hormones as it blends the advantages of both bacterial and mammalian expression systems. Earlier, expression of biologically active hCG and the subunits of hCG and bovine FSH using Pichia pastoris expression system has been reported from the laboratory (22, 23). Chapter 3 (section 3.3.1) of the thesis describes hyperexpression of hLH. The expression of these heterologous proteins was scaled up using fermentation procedures to fulfill the requirements of large quantities of hormones for various applications. Purification of Pichia expressed hormones turned out to be a complex task as large quantity of the hormone was secreted out in the fermentation medium (10litre volume) that was of high ionic strength. Of several different strategies attempted for concentration and partial purification of recombinant hCG, hydrophobic interaction chromatography (HIC) using Phenyl Sepharose matrix emerged as the most efficient technique as a first step of purification. Subsequently, cation exchange chromatography using SP- Sepharose matrix yielded completely purified biologically active recombinant hCG (section 3.3.2). The preliminary data also suggested that Pichia cells express a biologically active form of hCG which appeared to be less glycosylated and of lower molecular weight. Using the same protocol purification of hLH, as well as, single chain derivative of hCG, phCGαβ was achieved (section 3.3.3). These recombinant proteins were characterized extensively using various biochemical, as well as, immunological criteria and were shown to be similar to their natural counterparts with respect to their ability to bind LH receptor and to transduce signal as judged by radioreceptorassays and in vitro bioassays respectively. The hydrophobic interaction chromatography proved an important starting point for purification of all the other members of the glycoprotein hormone family expressed using Pichia pastoris expression system. With the availability of purified, biologically active recombinant hCG in large quantities it was now possible to make attempts towards structure elucidation using NMR spectroscopy. The structure determination of such complex proteins by NMR spectroscopy is made relatively easier by labeling the proteins with magnetically more active, stable isotopes of carbon and nitrogen, 13C and 15N respectively however the cost is often prohibitively high. The Pichia pastoris expression system offers simple means of labeling the proteins as the cells can be grown on simple salts of carbon and nitrogen such as 13C labeled methanol, 15N labeled ammonium chloride or ammonium sulphate. The Chapter 3 also gives a brief account of the preliminary attempts made to label the recombinant hCG with 15N and the structural studies carried out with the carbohydrate moieties of the recombinant hCG using solution NMR spectroscopy. This work was carried out in collaboration with the laboratory of Prof. J.P Kamerling of the University of Utrecht, Netherlands and the efforts are currently underway to elucidate the complete structure of the Pichia expressed hCG. The common feature of receptors and antibodies against the ligand is that both display very specific, high affinity binding towards the ligand. Hence, it is logical to speculate that the antigen binding regions of the antibodies that inhibit hormone binding and/or response, exhibit homology with distinct domains of the receptor. By identifying the epitopes recognized by such antibodies, it should be possible to predict contact points between the hormone and the receptor. In the present study, this hypothesis has been tested using monoclonal antibodies (MAbs) against hCG recognizing different epitopes in the hormone molecule and having different effects on hormone binding and response (Chapter 4). These MAbs were classified as α subunit specific, β subunit specific or heterodimer specific depending on their abilities to bind either subunit in addition to the hormone itself. Interestingly, it was observed that the hCGβ subunit specific MAbs, as well as, heterodimer specific MAbs inhibited hCG receptor binding and hence the response generated by hCG, while the hCGα subunit specific MAbs inhibited only response to the hormone without interfering in binding (Section 4.3.1). To dissect out these interactions further the epitopes recognized by these antibodies on hCG molecule were determined (Section 4.3.2), single chain fragment variable (ScFv) were generated from each of these antibodies and it was shown that these ScFv retain the functionality of the original antibody (Section 4.3.3). Further, the amino acid sequence of each antibody was determined (Section 4.3.4) and finally shown that the antigen binding domains of antibodies show homology to the distinct regions of the LH receptor on sequence alignments between the two using three different programs (4.3.5). The hCGβ subunit specific MAb 52/28' displayed distinct homology with the ECD of LH receptor while the α subunit specific MAb C10 showed regions homologous to TMD of the receptor and the heterodimer specific MAb E12 was found to be similar to the hinge region of the receptor. This clearly indicates that the β subunit of hCG is in close contact with ECD of the receptor while the α subunit makes contacts with the TMD of receptor. The present study thus supports the existing model of hormone receptor interactions, which states that the hormone first binds to the exodomain of the receptor mainly through its β subunit while the integrity of the α subunit is critical for signaling. (24, 25). Also, the observations made in the present study exhibit an interesting possibility of antigen antibody complexes being used as surrogate models for gaining insights into hormone receptor complex. Further, it has been reported that hCG has immunocontraceptive potential(26). Active and passive immunization studies with hCG in primates and humans have demonstrated the possibility of controlling fertility by the antibodies capable of neutralizing hCG. This forms the basis for female contraceptive vaccine that has undergone Phase II clinical trials in India. The MAb E12 characterized in the present study displayed highly specific binding to heterodimeric hCG exclusively without showing any cross reactivity with hLH (Section 4.3.1). The epitope mapping analysis revealed that this antibody recognizes a unique discontinuous epitope present only in the heterodimeric hCG and is distinct from the unique C-terminal extension of hCGβ absent in hLHβ (Section 4.3.2). The MAb, IgG or its recombinant single chain fragment variable (ScFv), inhibited response to hCG, but not to hLH (4.3.3). Thus, the epitope recognized by this MAb is an ideal candidate antigen for immunocontraception. The MAb E12 can also be used for passive immunization in case of emergency contraception. Another potential application of hCG specific antibodies is in homing and the treatment of tumors that secrete hCGβ subunit. The hCGβ subunit specific MAbs used in the present study 52/12 and 52/28' that inhibited hCG receptor binding as well as response generated by hCG can be used in treating such tumors. The functional ScFvs generated from these MAbs in the present study can be made use of on humanization. Thus, the present study has yielded some important molecules for therapeutic applications besides providing a new platform for structure-function relationship studies of the complex glycoprotein hormones.

L’ataxie spinocérébelleuse de type 3, aussi connue en tant que la maladie de Machado-Joseph (MMJ), est une maladie qui se développe lorsqu’il y a une expansion des trinucléotides CAG dans la région codante du gène ATXN3. Ce dernier code pour la protéine ATXN3, une enzyme désubiquitinante avec des fonctions essentielles dans le maintien et la stabilisation de l’homéostasie protéique, la résistance au stress, la régulation de la transcription, la réparation de l’ADN, l’organisation du cytosquelette et la régulation de la myogenèse. Les principaux symptômes associés à cette maladie sont l’ataxie (le symptôme clé), une détérioration motrice progressive, la dystonie, la spasticité et la rigidité. Du fait de l’absence de thérapie spécifique et efficace pour traiter les individus atteints de la MMJ, l’approfondissement des connaissances liées à cette maladie est nécessaire. Le but de cette thèse est de comprendre davantage les mécanismes et voies de signalisations impliqués dans la pathologie de la MMJ. Pour atteindre cet objectif, à partir de notre modèle transgénique C. elegans MMJ, deux différents criblages ont été effectués : un criblage non biaisé de 3942 composés, et un criblage de modificateurs génétiques à base d’ARN interférent (ARNi) de 387 clones de facteurs de transcription. Le premier criblage nous a permis d’identifier cinq molécules prometteuses : l’alfacalcidol, le chenodiol, le cyclophosphamide, le fenbufen et le sulfaphenazole. Elles ont permis la restauration du défaut de la motilité, la protection contre la neurodégénérescence, et une augmentation de la durée de vie réduite chez les vers mutants. Trois parmi ces molécules, le chenodiol, le fenbufen et le sulfaphenazole ont démontré une nécessité de la présence de HLH-30/TFEB, un régulateur clé de l’autophagie et de la biogenèse lysosomale, pour leurs propriétés neuroprotectrices. Concernant le deuxième criblage, il nous a permis d’identifier un nouveau gène candidat impliqué dans la MMJ, fkh-2/FOXG1. L’inactivation de ce gène a entraîné une aggravation du défaut de la motilité, de la neurodégénérescence, et de la longévité réduite. À l’inverse, sa surexpression a restauré tous ces phénotypes, suggérant ainsi un rôle neuroprotecteur pour FKH-2/FOXG1 dans la MMJ. Le modèle C. elegans de MMJ et les criblages sont des outils puissants permettant un approfondissement des connaissances quant à la pathologie de la MMJ. Pour cette thèse, par l’identification des molécules neuroprotectrices et les facteurs de transcription HLH-30/TFEB et FKH-2/FOXG1, ayant des activités neuroprotectrices dans notre modèle lorsqu’ils sont surexprimés, il a été possible à mieux comprendre la pathologie de la MMJ, ainsi que les mécanismes et les voies de signalisation qui y sont impliqués. Ces découvertes sont prometteuses à investiguer dans des organismes modèles plus avancés, des applications précliniques et également, pour le développement de nouvelles interventions thérapeutiques pour la MMJ. / Spinocerebellar ataxia type 3, also known as Machado-Joseph disease (MJD), is a polyglutamine expansion disease arising from a trinucleotide CAG repeat expansion in the coding region of ATXN3. This gene encodes ATXN3 protein, a deubiquitinating enzyme, which is involved in protein homeostasis maintenance and stabilization, stress resistance, transcription regulation, DNA repair, cytoskeleton organisation and myogenesis regulation. The main symptoms associated with this disease are ataxia (the key symptom), progressive motor deterioration, dystonia, spasticity and stiffness. Due to our incomplete understanding of mechanisms and molecular pathways related to this disease, there are no therapies that successfully treat core MJD patients. Therefore, the identification of new candidate targets related to this disease is needed. The aim of this thesis is to gain insights into the pathways and mechanisms leading to MJD. In order to achieve this goal, we performed two different screens, a blind drug screen of 3942 compounds to identify protective small molecules, and a large-scale RNA interference (RNAi) screen of 387 transcription factor genes leading to identification of modifiers involved in our transgenic C. elegans MJD model. The first screen allowed us to identify five lead compounds restoring motility, protecting against neurodegeneration, and increasing the lifespan in mutant worms. These compounds were alfacalcidol, chenodiol, cyclophosphamide, fenbufen and sulfaphenazole. We then found that three of these compounds, chenodiol, fenbufen and sulfaphenazole required HLH-30/TFEB, a key transcriptional regulator of the autophagy and the lysosomal biogenesis, to complete their neuroprotective activities. The second screen brought us to identify a news hit gene candidate involved in MJD, fkh-2/FOXG1. We showed that inactivation of this gene enhanced the motility defect, neurodegeneration and reduced longevity in our MJD model. However, in opposite, its overexpression rescued all these phenotypes, suggesting a neuroprotective role for FKH-2/FOXG1 in MJD when overexpressed. C. elegans models for MJD and the screenings are promising tools to understand the mechanisms and pathways causing neurodegeneration, leading to MJD. In this study, we identified positively acting compounds that may be promising candidates for investigation in mammalian models of MJD and preclinical applications in the treatment of this disease. Also, we gained insights into the pathways of MJD and found that HLH-30/TFEB and FKH-2/FOXG1 are both implicated in MJD and have neuroprotective activities when they are overexpressed. These promising findings may aid the development of novel therapeutic interventions for MJD.